These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32679052)

  • 1. Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits.
    Sewell F; Kimber I; Boobis AR
    Regul Toxicol Pharmacol; 2020 Oct; 116():104734. PubMed ID: 32679052
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management.
    Heringa MB; Cnubben NHP; Slob W; Pronk MEJ; Muller A; Woutersen M; Hakkert BC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104659. PubMed ID: 32334038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel approach to calculating the kinetically derived maximum dose.
    Burgoon LD; Fuentes C; Borgert CJ
    Arch Toxicol; 2022 Mar; 96(3):809-816. PubMed ID: 35103817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.
    Chapman K; Sewell F; Allais L; Delongeas JL; Donald E; Festag M; Kervyn S; Ockert D; Nogues V; Palmer H; Popovic M; Roosen W; Schoenmakers A; Somers K; Stark C; Stei P; Robinson S
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):27-38. PubMed ID: 23602904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking guideline toxicity testing.
    Saghir SA
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):423-8. PubMed ID: 25980640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 3Rs in research: a contemporary approach to replacement, reduction and refinement.
    MacArthur Clark J
    Br J Nutr; 2018 Aug; 120(s1):S1-S7. PubMed ID: 29081302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship Between Internal and External Dose: Some General Results Based on a Generic Compartmental Model.
    Slob W; Zeilmaker MJ; Hoogenveen RT
    Toxicol Sci; 2020 Sep; 177(1):60-70. PubMed ID: 32514576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing--an integrated approach without additional animal use.
    Saghir SA; Bartels MJ; Rick DL; McCoy AT; Rasoulpour RJ; Ellis-Hutchings RG; Sue Marty M; Terry C; Bailey JP; Billington R; Bus JS
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):321-32. PubMed ID: 22440553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afidopyropen: Challenges and impact of a toxicokinetic study designed to identify a point of inflection from dose-proportionality.
    Loccisano AE; Freeman E; Riffle B; Doi A; Frericks M; Fegert I; Fabian E
    Regul Toxicol Pharmacol; 2021 Aug; 124():104962. PubMed ID: 34019964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of toxicokinetic data for afidopyropen to determine the dose levels in developmental toxicity studies.
    Loccisano AE; Bus J; Gollapudi B; Riffle B; Frericks M; Fegert I; Fabian E
    Regul Toxicol Pharmacol; 2020 Jun; 113():104644. PubMed ID: 32194133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of the maximum tolerated dose (MTD) and maximum tolerated concentration (MTC) concept in aquatic toxicology.
    Hutchinson TH; Bögi C; Winter MJ; Owens JW
    Aquat Toxicol; 2009 Feb; 91(3):197-202. PubMed ID: 19124163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety.
    Borgert CJ; Fuentes C; Burgoon LD
    Arch Toxicol; 2021 Dec; 95(12):3651-3664. PubMed ID: 34623454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for Refinement of Non-Human Primate Vaccine Studies.
    Prescott MJ; Clark C; Dowling WE; Shurtleff AC
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33808708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities to Apply the 3Rs in Safety Assessment Programs.
    Sewell F; Edwards J; Prior H; Robinson S
    ILAR J; 2016 Dec; 57(2):234-245. PubMed ID: 28053076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of mouse lung tumors to human risk assessment.
    Cohen SM; Zhongyu Y; Bus JS
    J Toxicol Environ Health B Crit Rev; 2020 Jul; 23(5):214-241. PubMed ID: 32452303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANIMAL WELFARE FROM MOUSE TO MOOSE--IMPLEMENTING THE PRINCIPLES OF THE 3RS IN WILDLIFE RESEARCH.
    Lindsjö J; Fahlman Å; Törnqvist E
    J Wildl Dis; 2016 Apr; 52(2 Suppl):S65-77. PubMed ID: 26845301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Researchers' attitudes to the 3Rs-An upturned hierarchy?
    Franco NH; Sandøe P; Olsson IAS
    PLoS One; 2018; 13(8):e0200895. PubMed ID: 30110335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.
    Paranjpe MG; Denton MD; Vidmar TJ; Elbekai RH
    Toxicol Pathol; 2015 Jul; 43(5):611-20. PubMed ID: 25391312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3Rs in animal welfare bodies at Swedish universities - knowledge, attitudes, implementation.
    Lindsjö J; Berg C; Olsson U; Törnqvist E
    ALTEX; 2021; 38(3):477-489. PubMed ID: 33786636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.